Abstract GS2-06: Patient Reported Outcomes Following Active Monitoring or Surgery (+/- Radiation) for Low Risk DCIS in the Comparing an Operation to Monitoring, with or without Endocrine Therapy (COMET) Study (AFT-25)
Ann H. Partridge(Dana-Farber Cancer Institute), Shelley Hwang(Duke University), Elizabeth S. Frank(Dana-Farber Cancer Institute), Shoshana M. Rosenberg(Dana-Farber Cancer Institute), Alastair M. Thompson(Baylor College of Medicine), Amy Krie(Amgen (United States)), Kathleen J. Yost(Michigan Cancer Research Consortium), Antonia V. Bennett(Memorial Sloan Kettering Cancer Center), Kelsey E. Larson(Cleveland Clinic), Marc Boisvert, Sarah Drier(University of North Carolina at Chapel Hill), Meredith Witten(Aurora Health Care), Lisa Carey, Terry Hyslop(Thomas Jefferson University), Priscilla F. McAuliffe(University of Pittsburgh), Thomas Lynch(Duke University), Deborah Collyar(Advocates for Youth), Anna Weiss(University of Rochester), Li Yan(Sanford Burnham Prebys Medical Discovery Institute), Ayako Shimada(Thomas Jefferson University), Mattias Jönsson(University of North Carolina at Chapel Hill), Armando E. Giuliano(Cedars-Sinai Medical Center), Anna Wolf(University Medical Center), Desiree Basila(Alliance Foundation Trials), Donna Pinto, Sonja Darai(Dana-Farber Cancer Institute), Nina P. Tamirisa(The University of Texas MD Anderson Cancer Center), Yutong Li(Thomas Jefferson University)
Cited by 0
Related Papers
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
|New England Journal of Medicine|2016|2k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k